E-mail Comment Del.icio.us Digg Reddit Technorati Furl

MethylGene and Pharmion Expand Collaboration on Epigenetic Therapies

Aug 20, 2007 cancer, investors

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a “research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.”

MethylGene and Pharmion’s Class I specific HDAC inhibitor, MGCD0103, has demonstrated efficacy in a number of tumor types, and the sirtuins represent potentially attractive novel cancer targets within a related family of enzymes. Sirtuins (including SIRT1) have been shown to deacetylate histone proteins and numerous transcription factors, leading to promotion of normal cell survival and aberrant gene silencing in cancer cells. Inhibition of sirtuins allows reexpression of silenced tumor suppressor genes, leading to reduced growth of cancer cells, and anti-cancer effects have been observed with SIRT1 inhibitors in vitro and in vivo. As yet, no sirtuin inhibitors have entered the clinic. Synergies in gene reexpression have been demonstrated by combining SIRT1 inhibition with either standard cytotoxics or other epigenetic modifying drugs, including inhibitors of DNA methylation and histone deacetylation. Two epigenetic therapy combinations are already under active investigation in Phase II studies combining Pharmion’s Vidaza, a DNA hypomethylating agent, with MethylGene and Pharmion’s HDAC inhibitor, MGCD0103. The parties intend to explore combinations with resulting anti-sirtuins as well.

Link

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

This entry was posted on Monday, August 20th, 2007 at 12:40 pm and is filed under cancer, investors. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

One Response to “MethylGene and Pharmion Expand Collaboration on Epigenetic Therapies”

  1. Gene Genie #14: Bugs and Beyond « MicrobiologyBytes Says:

    August 25th, 2007 at 6:29 pm

    [...] Finally, the industry buzz is mostly around Navigenics, and 23andMe, two companies who want you to spit into a cup so they can profile your genome, commented on by business|bytes|genes|molecules, My Biotech Life, and Venture Beat, but Gene Sherpa is bothered by the ethics surrounding the promise to alter your future… by email. Epigenetics News finishes up the industry theme in describing a new collaboration on epigenetic therapies. [...]